Which category does mitotane belong to in the drug classification?

Mitotane is a unique antineoplastic drug primarily used to treat adrenocortical carcinoma (ACC) (adrenal cancer), a rare and aggressive malignant tumor of the adrenal gland. In terms of drug classification, mitotane is an adrenocortical cytotoxic drug and is also classified as a fat-soluble steroid drug. Its mechanism of action is different from traditional cytotoxic chemotherapy drugs. It mainly achieves the effect of selectively killing adrenocortical tumor cells by destroying the mitochondrial function and metabolic activity of adrenocortical cells.

From a broader classification perspective, mitotane is an endocrine therapy drug among anti-tumor drugs because it acts directly on the endocrine glands (adrenal glands) and inhibits the growth of adrenocortical cancer by interfering with the synthesis and secretion of hormones. Its structure is similar to the pesticide dichlorodiphenyltrichloroethane (DDT), so it has strong fat solubility and can be highly accumulated in adipose tissue and adrenal tissue. This characteristic gives it a long half-life and sustained effect during treatment.

Mitotane induces the dysfunction of multiple enzyme systems in the mitochondria of adrenocortical cells, especially interfering with the activity of key enzymes in the steroid hormone synthesis pathway, thereby reducing the production of cortisol and other adrenal hormones. It has both a direct cytotoxic killing effect and an indirect endocrine inhibitory effect, allowing patients with adrenocortical cancer to control their tumors and at the same time alleviate clinical symptoms caused by abnormal hormone secretion, such as Cushing's syndrome.

Mitotane is often used clinically in combination with hydrocortisone or other glucocorticoid replacement therapy to deal with drug-induced adrenal insufficiency. Its unique pharmacological properties make it an important drug in the current treatment of adrenocortical cancer, especially suitable for postoperative adjuvant therapy and for advanced patients who cannot be surgically removed. It is worth noting that the dosage adjustment and monitoring of mitotane need to be done carefully to balance the efficacy and side effects.

Reference materials:https://go.drugbank.com/drugs/DB00648